EMA lays out workplan to maximize AI benefits, managerisks| Bio World
With the use ofartificial intelligence(AI) increasing in both biopharma R&D and the regulatory science used to evaluate new drug candidates in …
Read the original at BioWorld ↗
- Topics
- Regulation & PolicyHealthcare
- Tags
- AI Use Case
- Tracked via
- Google Alert “AI Risks”